id: diabetes_diagnosis_to_NEW:lean_nafld
name: Type 2 Diabetes Mellitus Diagnosis â†’ Nonalcoholic Fatty Liver Disease in Lean
  Individuals
from_node:
  node_id: diabetes_diagnosis
  node_name: Type 2 Diabetes Mellitus Diagnosis
to_node:
  node_id: NEW:lean_nafld
  node_name: Nonalcoholic Fatty Liver Disease in Lean Individuals
direction: positive
category: biological
mechanism_pathway:
- 'Step 1: Type 2 diabetes mellitus creates a state of insulin resistance and hyperinsulinemia
  that affects hepatic lipid metabolism even in individuals without obesity'
- 'Step 2: Insulin resistance promotes de novo lipogenesis in the liver while simultaneously
  impairing fatty acid oxidation, leading to intrahepatic triglyceride accumulation'
- 'Step 3: The metabolic dysfunction associated with T2DM (dyslipidemia, hyperglycemia)
  drives hepatic steatosis development independent of overall body mass index'
- 'Step 4: Accumulated hepatic fat triggers inflammatory pathways and oxidative stress,
  potentially progressing to nonalcoholic steatohepatitis and fibrosis in lean individuals'
evidence:
  quality_rating: B
  n_studies: 4
  primary_citation: 'M. Long et al. 2022. AGA Clinical Practice Update: Diagnosis
    and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert
    Review. Gastroenterology.'
  supporting_citations: []
description: Type 2 diabetes mellitus is a significant risk factor for nonalcoholic
  fatty liver disease in lean individuals (BMI <25 kg/m2 for non-Asians, <23 kg/m2
  for Asians). The AGA Clinical Practice Update recommends screening for NAFLD in
  T2DM patients over 40 years and emphasizes that T2DM should prompt consideration
  of NAFLD even in lean individuals. An estimated 7-20% of NAFLD cases occur in lean
  individuals, and T2DM is a key metabolic comorbidity driving this condition. Lean
  individuals with NAFLD face increased cardiovascular, liver, and all-cause mortality.
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
moderators:
- name: ethnicity
  direction: strengthens
  strength: moderate
  description: Asian populations may have higher susceptibility to lean NAFLD at lower
    BMI thresholds, requiring different diagnostic cutoffs
- name: age
  direction: strengthens
  strength: moderate
  description: Screening for NAFLD recommended in T2DM patients older than 40 years,
    suggesting age modifies risk
- name: dyslipidemia
  direction: strengthens
  strength: moderate
  description: Co-existing dyslipidemia in T2DM patients increases NAFLD risk in lean
    individuals
- name: hypertension
  direction: strengthens
  strength: moderate
  description: Comorbid hypertension compounds metabolic risk for lean NAFLD development
